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Abstract Despite current advances in therapy, the prognosis
of patients with glioblastoma has not improved sufficiently in
recent decades. This is due mainly to the highly invasive
capacity of glioma cells. Little is known about the mecha-
nisms underlying this particular characteristic. While the Rho-
kinase (ROCK)-dependent signaling pathways involved in
glioma migration have yet to be determined, they show prom-
ise as one of the candidates in targeted glioblastoma therapy.
There are two ROCK isoforms: ROCK1, which is upregulated
in glioblastoma tissue compared to normal brain tissue, and
ROCK2, which is also expressed in normal brain tissue.
Blockage of both of these ROCK isoforms with pharmaco-
logic inhibitors regulates the migration process. We examined
the activities of ROCK1 and ROCK2 using knockdown cell
lines and the newly developed stripe assay. Selective knock-
down of either ROCK1 or ROCK2 exerted antidromic effects
on glioma migration: while ROCK1 deletion altered the
substrate-dependent migration, deletion of ROCK2 did not.
Furthermore, ROCK1 knockdown reduced cell proliferation,
whereas ROCK2 knockdown enhanced it. Along the signal-
ing pathways, key regulators of the ROCK pathway are dif-
ferentially affected by ROCK1 and ROCK2. These data sug-
gest that the balanced activation of ROCKs is responsible for
the substrate-specific migration and the proliferation of glio-
blastoma cells.
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Introduction
Glioblastoma multiforme (World Health Organization grade
IV), which is the most common brain tumor in humans, has a
median survival time of only 12–14 months. One reason for
this poor prognosis is the ability of single tumor cells to invade
diffusely into the neighboring brain parenchyma. After tumor
resection followed by adjuvant radiation and chemotherapy,
90 % of patients are subject to recurrences within months,
usually in the tissue adjacent to the resection area [1]. There-
fore, any efficient therapeutic approach must reach cells that
have invaded far beyond the radiologically and intraoperative-
ly visible borders because cells migrate along the white matter
tracts and basement membranes of blood vessels [2–6].
Key players in the process of glioma migration seem to be
the Ras homolog gene family (Rho)-associated protein ki-
nases (ROCKs) [7–9]. The two ROCK isoforms, ROCK1
and ROCK2, act downstream of the small GTPase Rho mem-
ber A (RhoA). The ROCK1 and ROCK2 peptides display
some similarities in the kinase activity domain at the N-
terminus, the coiled-coil domain, and a pleckstrin homology
(PH) domain at the C-terminus. GTP-bound RhoA activates
the Rho kinases by displacement of the PH domain, thus
enabling different substrates to bind to the kinase domain
[10, 11]. LIM kinase (LIMK) is activated by phosphorylation
through ROCKs. This activation leads to a phosphorylation of
cofilin, which in turn inhibits actin depolymerization, leading
to a consequent increase in actin polymerization. Furthermore,
ROCKs also phosphorylate the myosin-binding subunit of
myosin phosphatase, leading to the inactivation of the phos-
phatase activity [12]. ROCKs also mediate—at least in part—
a translocation of Rho signaling to the nucleus, where Rho
regulates the functions of various transcription factors includ-
ing the four and a half LIM domains protein (FHL2) and
estrogen receptor (ER) [13, 14]. While integrins and matrix
metalloproteases are typically involved in the mesenchymal
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type of migration, ROCKs are involved in amoeboid move-
ment and migration [15].
Recently, we have established a co-culture migration assay
that allows cells to migrate along myelinated axons, with a
view to examine the molecular mechanisms underlying tumor
cell migration along white matter tracts using pharmacological
ROCK inhibition [16]. Furthermore, we established a modi-
fied stripe assay to determine the substrate specificity changes
of glioma cells under ROCK inhibition by using the unselec-
tive inhibitor Y27632 [17].
In the present study, we investigated whether the shRNA-
induced inhibition of either ROCK1 or ROCK2 alone influ-
ences glioma migration and proliferation and elucidated the
differences between these two ROCKs in glioblastoma cell
migration, substrate preferences, and cell proliferation. We
were able to show that ROCK1 alone is capable of inducing




Human glioblastoma cell lines U87MG, U343MG, 86HG39,
U373MG, D54MG, H4, T98G, and A172 (all cell lines are
kind gifts of V. Senner, Institute of Neuropathology, Muenster,
Germany) were cultured in Dulbecco’s modified Eagle’s min-
imal essential medium (DMEM) with 10 % fetal calf serum,
100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C in
5 % CO2 (all cell culture reagents were purchased from PAA,
Linz, Austria).
Stable Transfection
Four different shRNA oligonucleotides for ROCK1 inhibition
[sure silencing shRNA plasmid ROCK1 hygromycin
(KH01966H)], including one negative control vector and four
different shRNA oligonucleotides for ROCK2 knockdown
[sure silencing shRNA plasmid ROCK2 hygromycin
(KH09606H)] were purchased from SA Biosciences (Hilden,
Germany). Cells were seeded at a density of 0.8×105 in 24-
well plates with 500 μl of culture medium the day before
shRNA transfection. Cells were transfected by adding
Attractene Transfection Reagent (Qiagen) according to the
manufacturer’s recommendations and maintained in culture
medium for 24 h before selection with 600 μg/ml
hygromycin. After colony formation, at least 60 independent
clones were chosen for each vector sequence. The extent of
RNA knockdown under these conditions was determinedwith
quantitative real-time polymerase chain reaction (qRT-PCR)
analyses, Western blotting, and immunostaining.
Immunoblotting
Lysis of cells and tissue, sodium dodecyl sulfate polyacryl-
amide gel electrophoresis, and immunoblotting were conduct-
ed as described [17]. Rabbit anti-ROCK1 antibody (Sigma-
Aldrich, 1:1,000 dilution), rabbit anti-ROCK2 antibody (Sig-
ma-Aldrich, 1:1,000 dilution), anti-rabbit phospho-LIMK1/
LIMK2 (Cell Signaling, 1:1,000 dilution), anti-rabbit
phosphoCdc42/rac (Cell Signaling, 1:1,000 dilution), anti-
mouse RhoA (Abcam, 1:300 dilution), anti-rabbit phosphor-
Akt1 (Abcam, 1:1,000), anti-mouse Akt1 (Abcam, 1:300
dilution), anti-mouse cyclin D1 (Abcam, 1:1,000 dilution),
anti-goat β1-integrin (Santa Cruz Biotechnology, 1:200 dilu-
tion), anti-mouse β-catenin (BD Biosciences, 1:2,000 dilu-
tion), and anti-rabbit phosphoERK1/2 (Cell Signaling, 1:500
dilution) were used. Peroxidase-conjugated goat anti-rabbit
(Cell Signaling) or goat anti-mouse secondary antibody (Cell
Signaling), at a dilution of 1:5,000 for 1 h at room tempera-
ture, was used. To verify equal protein loading on each lane,
the blots were stripped and reprobed for rabbit anti-calnexin
(Sigma-Aldrich, 1:20,000 dilution), mouse anti-β-actin (Sig-
ma-Aldrich, dilution 1:20,000), or rabbit anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; Sigma-Aldrich, 1:200,
000 dilution). For analyzing the results, lanes were quantified
using densitometry (AlphaEraseFC Software), and loading
controls (calnexin, GAPDH, or β-actin) were used for
standardization.
Immunofluorescence
After permeabilizing the cells with 0.1 % Triton X-100
(Sigma) in phosphate-buffered saline (PBS), they were
blocked with 0.5 % bovine serum albumin in PBS. The rabbit
ROCK1 and ROCK2 antibodies were applied to separate
groups of cells at a dilution of 1:100 and incubated at 4 °C
overnight. A tetramethylrhodamine/isothiocyanate-
conjugated anti-mouse antibody (T1689, Sigma, 1:200 dilu-
tion) was used as the secondary antibody. Actin filaments
were visualized by incubating the cells for 30 min with fluo-
rescein isothiocyanate (FITC)–phalloidin. The cell nuclei
were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) and then mounted in anti-fading medium Mowiol
(Merck, Darmstadt, Germany). Fluorescence was documented
using an Axiophot microscope (Zeiss) with AxioVision Soft-
ware (Zeiss).
qRT-PCR Analyses
Total RNA was isolated from sub-confluent cultured cells
using an RNeasy Plus Mini kit (Qiagen). Total RNA (1 μg)
was transcribed into cDNA with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA) in a reaction volume of 20 μl. After cDNA
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synthesis, 1 μl from the reaction volume was used for qRT-





Relative RNA levels were calculated and compared between
shRNA- and control-transfected cells. The data were normal-
ized relative to those for GAPDH using the following primers:
TGCACCACCAACTGCTTAGC (GAPDH, forward)
GGCATGGACTGTGGTCATGAG (GAPDH, reverse)
The relative expressions were calculated using the 2−ΔΔCT
method. All measurements were conducted in duplicate and
the experiments were repeated at least three times.
Wound-Healing Assay
Cell migration was analyzed using a wound-healing assay. Brief-
ly, cells were seeded at a density of 0.8×105 per well in a 24-well
plate. After 24 h, cell monolayers were scratched using the back
side of a standard 100-μl pipette tip. After being washed three
times with PBS, photomicrographs were taken of the scratches,
including the flanking front lines of cells (at ×40 magnification),
and then incubated under standard conditions. Migration into the
scratched area was documented at 24 and 48 h after wounding.
Scratch closure by migrating cells was compared between
ROCK1/ROCK2 knockdown cells and control-transfected cells.
Wound closing was evaluated relative to the total area of
wounding by counting the migrating cells using a light micro-
scope (Zeiss) and TScratch Software (CSE Lab, Zurich, Swit-
zerland). Experiments were performed independently three
times, with four to eight scratches being evaluated for each
experimental condition.
Monolayer Migration and Proliferation Assay
Permanox LabTek eight-well chamber slides (Nunc,
Langenselbold, Germany) were coated with poly-L-lysine and
Matrigel solution (BD Biosciences) 24 h before use. The cham-
bers were filled with a 200-μl volume of pre-warmed DMEM,
after which sterile glass sedimentation cylinders were placed in
each chamber. Cells in DMEM were seeded at a density of 2×
103 into the lumen of the cylinders in a volume of 2 μl. The
cylinders were removed after the cells had been allowed to
adhere to the substrate (16–24 h after seeding). The resulting
colonies were photographed immediately after removal of the
cylinders and again at intervals of 24 and 48 h thereafter. Cell
migration was evaluated by measuring the increase in the area of
the colonies using ZEN software (Zeiss). The change in the area
of each colony at each time point was standardized against the
colony area measured from the photograph taken immediately
after removal of the cylinders. Cellular proliferation of ROCK1




The principle of the stripe assay is that the cells can choose
between the different surfaces during migration, so that any
differences in affinity, motility, and cell proliferation can be
observed [17]. The cells were seeded onto the stripped mem-
branes at a concentration of 0.8×105 cells/ml and allowed to
migrate for 48 h. They were then fixed in 4 % paraformalde-
hyde and transferred to glass coverslips. The stripes were
visualized by staining the substrates with FluoSpheres before
they were applied to the membranes; the cells were stained
with DAPI after fixation. Cell quantification was achieved by
first photographing the membranes (at least 15–20 photo-
graphs per membrane) and then counting the cells on the
different stripes using ImageJ software. The chosen stripe
components were homogenized rat retina free of myelin and
myelin-containing perinatal rat brains. Biomatrix (BM),
which is commercially available, was chosen as the extracel-
lular matrix (Serva, Mannheim, Germany).
Statistics
The results are presented as the mean ± SEM percentage values.
Statistical significancewas analyzed using paired Student’s t test;
the level of statistical significance was set at p<0.05.
Results
Expression Analyses and Stable Knockdown of the ROCKs
Seven glioma cell lines were first evaluated to screen for the
best cell line for stable knockdown of both ROCKs. At the
mRNA level, the 86HG39 and D54MG cell lines displayed
the strongest expression of ROCK1, while the strongest ex-
pressions of ROCK2 were found in the U373MG and
86HG39 cell lines (Fig. 1a, b). The expression levels of
ROCK1 and ROCK2 proteins differ from the mRNA results;
here, we found the highest expression for ROCK1 in the cell
lines D54MG and U373MG and for ROCK2 in D54MG,
86HG39, and U353MG (Fig. 1c, d). Because of the expres-
sion levels and the genetic aspects of the cell lines [19, 20], we
decided to use D54MG and 86HG39 human glioma cell lines
for further investigations. To reveal the cellular location of
ROCK1 and ROCK2 in both cell lines, we performed fluo-
rescence immunohistology staining (Fig. 1e, f). Both proteins
show a cytoplasmic and membrane-associated location in
human glioblastoma cell lines.
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To avoid off-target effects, we used two different shRNA
vector sequences (referred to as seq1 and seq3 for ROCK1
and seq2 and seq4 for ROCK2) and a vector control to induce
the knockdown, and at least 60 different clones were screened
for each vector construct and each cell line. The reduction of
both ROCK1 and ROCK2 expressions in the selected clones
was verified using qRT-PCR analyses and Western blotting.
ROCK1 mRNA expression in the D54MG cell line was
reduced to 16.6 % for sequence 1 clone 4 (D54MG seq1)
and to 14.4 % for sequence 3 clone 13 (D54MG seq3). The
knockdown of ROCK1 was more efficient in the 86HG39 cell
line, with an expression level of 7.0 % for sequence 1 clone 12
(86HG39 seq1) and of 9.4 % for sequence 3 clone 10
(86HG39 seq3; Fig. 2a). ROCK2 mRNA expression in the
D54MG cell line was reduced to 13.4 % for sequence 2 clone
2 (D54MG seq2) and to 5.7 % for sequence 4 clone 39
(D54MG seq4); that in the 86HG39 cell line was 2.7 % for
sequence 2 clone 52 (86HG39 seq2) and 3.9 % for sequence 4
clone 3 (86HG39 seq4; Fig. 2b). A distinct reduction in the
level of protein expression of ROCK1 (Fig. 2c) and ROCK2
(Fig. 2d) was also found in all four clones. D54MG seq1 has a
ROCK1 protein level of 34.0% and seq3 of 74.4%; in the cell
line 86HG39, we found ROCK1 protein levels of 79.7 %
(seq1) and 47.0 % (seq3; Fig. 2f). ROCK2 protein level was
also affected by ROCK1 knockdown (Fig. 2g). Here, we
found a reduced ROCK2 expression in D54MG seq1
(79.5 %) and in 86HG39 seq3 (39.8 %). The knockdown of
ROCK2 leads to ROCK2 protein levels of 51.7 and 87.8% for
D54MG seq2 and seq4 and of 53.9 and 33.2 % for 86HG39
seq2 and seq4. Analysis of the ROCK1 protein expression in
ROCK2 knockdown clones exhibits no changes. The inhibitor
Y27632 affects both kinases ROCK1 and ROCK2. ROCK1
protein expression in the cell line D54MG was reduced to
63.3% and in the cell line 86HG39 to 61.5%. ROCK2 protein
level shows reduction to 58.1 % for D54MG and only a slight
effect on 86HG39 to 98.2 % (Fig. 2e–g).
ROCK1 and ROCK2 Influence Cell Proliferation and Change
Cell Morphology
Next, we determined whether the effects of ROCK1/ROCK2
knockdown on cell migration are based on changes in cell
proliferation. A significant decrease in cellular growth was
observed in ROCK1-deficient cells relative to the vector con-
trols (set as 100 %). For all of the used ROCK1 knockdown
clones, pronounced changes in proliferation were observed at
72 h (D54MG: sequence 1=39.4±14.9 %, sequence 3=50.2±
16.9 %; 86HG39: sequence 1=53.7±15.4 %, sequence 3=
69.2±12.4 %; Fig. 3a). Conversely, knockdown of ROCK2
enhanced cell proliferation. The maximum proliferation rate
was found at 72 h for both cell lines (D54MG: sequence 2=
216.1±16.0 %, sequence 4=238.0±5.4 %; 86HG39: se-
quence 2=130.3±8.0 %, sequence 4=147.7±8.3 %; Fig. 3b).
Immunofluorescence staining for ROCK1/ROCK2 and
FITC–phalloidin were used to determine whether knockdown
of ROCK1 and ROCK2 alters the cellular phenotype. All of
the ROCK1 knockdown clones displayed changes in cell
morphology and developed a mesenchymal-like phenotype.
Inhibition of ROCK1 and ROCK2 led to several cytoskeletal
and morphologic changes including inhibition of stress fibers,
enhancement of the number and length of cell processes, and
an increase in the degree of membrane ruffling (Fig. 2h, i).
The knockdown cells displayed a stellar appearance with an
increase of the number and length of actin-positive membrane
ruffles. These data show that there is no distinct difference in
the change in cell phenotype between ROCK1 and ROCK2
knockdown cells.
Differential Effects on Cell Migration of ROCK1 and ROCK2
Functional analysis of the effects of ROCK1 and ROCK2
knockdown on cell migration was conducted with uncoated
wound-healing migration assays as well as radial monolayer
assays coated with laminin, respectively. Simultaneous inhi-
bition of both ROCK1 and ROCK2 was performed using a
monolayer migration assay on a laminin-coated surface with
D54MG and 86HG39 cells using the ROCK inhibitor
Y27632. A significant reduction in cell migration was found.
In the D54MG cell line, the addition of 100 μM Y27632
resulted in migration rates of 46.8±6.4 and 51.3±8.1 % at
24 and 48 h, respectively. In the 86HG39 cell line, simulta-
neous inhibition of both ROCK1 and ROCK2 reduced the cell
migration rates to 38.7±3.5 and 68.2±2.3 % at 24 and 48 h,
respectively (Fig. 4a). ROCK1 and ROCK2 knockdown cells
were separately subjected to repeated migration assays in
order to establish whether the reduction in migration observed
when both ROCK1 and ROCK2 are inhibited is based on the
reduction of both or whether reduction of either kinase is
sufficient to account for the effect.
When ROCK1 protein synthesis was inhibited in the
D54MG cell line, the cells migrated faster on an uncoated
surface, at rates of 168.9±2.5 % (seq1) and 160.8±2.4 %
(seq3) at 24 h and of 167.0±1.9 % (seq1) and 156.8±1.1 %
(seq3) at 48 h relative to the migration rate of the control cells
(set as 100 %; ±1.0 % at 24 h, ±3.1 % at 48 h). Similar results
were observed with the 86HG39 cell line, for which the
wound closing rates were 136.2±0.6 % (seq1) and 145.7±
0.4 % (seq3) at 24 h and 156.7±0.9 % (seq1) and 144.6±
0.6 % (seq3) at 48 h (Fig. 4b). Thus, knockdown of ROCK1
leads to a highly significant increase in cell migration on an
uncoated surface. In contrast, ROCK1 knockdown cells
displayed a significant decrease in cell migration on the radial
monolayer coated with laminin. With the D54MG cell line,
there were reductions in the migration rate of 68.0±3.7 %
(24 h) and 53.2±4.8 % (48 h) for sequence 1 and of 58.5±
6.3 % (24 h) and 47.7±5.2 % (48 h) for seq3 (relative to the
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control, set as 100% for all time points). The 86HG39 cell line
exhibited a comparable inhibition of cell migration on the
laminin-coated surface under ROCK1 knockdown, whereby
the migration rates were reduced (relative to control, set as
100 %) to 52.7±2.6 % (24 h) and 51.9±5.3 % (48 h) for seq1
and to 44.3±2.3 % (24 h) and 58.5±6.2 % for seq3 (Fig. 4d).
Together, these findings show that ROCK1 knockdown leads
to a substrate-dependent migration effect, with enhanced mi-
gration on an uncoated surface and reduced migration on a
laminin-coated surface (Fig. 4b, d).
Fig. 1 ROCK1 and ROCK2 protein and mRNA expressions in different
human glioblastoma cell lines. Quantitative real-time PCR analyses of
ROCK1 (a) and ROCK2 (b) mRNA in different glioblastoma cell lines
reveal the highest amount of ROCK1 mRNA in the cell lines 86HG39
and D54MG and the highest amount of ROCK2 mRNA in 86HG39 and
U373MG. Western blot analyses of ROCK1 (c) and ROCK2 (d) protein
expressions in commonly used glioblastoma cell lines display an
increased ROCK1 protein expression in the cell lines U373MG and
D54MG and an increased ROCK2 expression in the cell lines 86HG39,
D54MG, and U343MG. Immunofluorescence staining of 86HG39 and
D54MG glioma cell lines using antibodies raised against ROCK1 (e) and
ROCK2 (f) and FITC–phalloidin (green ; to stain the cytoskeleton) shows
cytoskeleton- and membrane-associated location of ROCK1 and ROCK2
in both cell lines used
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In contrast to ROCK1 knockdown, ROCK2 knockdown
increased the migration rate in both assays. Migration on the
uncoated surface was significantly increased (relative to the
control of 100±2.1 %) for both cell lines and for all tested
clones, at 141.0±16.8 % for 86HG39 seq4 at 48 h and 273.0±
16.8 % for 86HG39 seq2 at 24 h (Fig. 4c). On the radial
monolayer migration assay with a laminin-coated surface, the
migration rate relative to the control was 123.6±11.8 % for
D54MG seq4 at 48 h and 213.6±11.8 % for 86HG39 seq4 at
24 h. These data show that the reduction in ROCK2 expres-
sion in both glioblastoma cell lines led to a substrate-
independent increase in migration (Fig. 4e). The cell migra-
tion effects of the two ROCKs thus differ in that those of
ROCK1 are substrate-dependent whereas those of ROCK2
are independent of the substrate.
Knockdown of ROCK1, But Not ROCK2, Leads
to a Significant Change in the Substrate Specificity
of Tumor Cells
The stripe assay, which allows cells to be confronted simulta-
neously with two different substrates [21], was used to further
examine the effects of the ROCKs on cell migration. In a
previous study, we showed that glioma cells have a distinct
preference for the extracellular matrix compared to all other
substrates [17]. To reflect the components of an intact 3D brain
environment, membrane fractions from unmyelinated rat retina
were used to represent gray matter, along with purified myelin
and BM, and all three substrates were tested against each other
usingROCK1 andROCK2 knockdown cell lines and the control
cell lines. Furthermore, the ROCK inhibitor Y27632was applied
to the ROCK1 knockdown cells and the controls to elucidate
whether Y27632 has an additive effect.
The untreated control cells of both cell lines used (D54MG
and 86HG39) again exhibited a distinct preference for BM,
followed by myelin. All of the ROCK1 knockdown clones of
these cell lines with two different shRNA vector sequences
changed their preference for BM when tested against myelin.
BM and myelin contained 70.4±1.6 and 29.6±1.63 % of the
D54MG control cells, respectively. The ROCK1 knockdown
clone seq1 seemed to lose preference for BM since the cells
were distributed similarly on the two types of stripe (56.3±
2.51 % on BM vs. 43.7±2.51 % on myelin). Comparable
results were obtained for clone seq3, with 53.3±2.44 % of
the cells being located on BM and 46.7±2.44 % on myelin.
The application of Y27632 to ROCK1 knockdown cells re-
sulted in a complete reversal of their preference. Even in the
Fig. 3 Proliferation analyses of cells with reduced ROCK1 and ROCK2
expressions compared to control cells. The knockdown of ROCK1 led to
a significant decrease in cell proliferation in both cell lines (D54MG and
86HG39) and in both cell clones used per cell line (sequence1 and
sequence3) relative to the control (set as 100 %) for up to 72 h (a),
whereas the inhibition of ROCK2 expression in the cell lines led to an
increase in proliferative activity (b), as assessed with the MTT assay.
Asterisks represent the representative p values (*p <0.05; **p <0.001,
n =3, mean±SEM)
Fig. 2 Verification of ROCK1 and ROCK2 knockdown in the human
glioblastoma cell lines 86HG39 and D54MG at the mRNA and protein
levels. Knockdown of ROCK1 using two different shRNA sequences
(seq1 and seq3) and a vector control (set as 100 %) in D54MG and
86HG39 cell lines at the mRNA (a) level shows a reduction of ROCK1
mRNA expression level in D54MG cells to 16.6 and 14.4 % and in
86HG39 cells to 7.0 and 9.4 %. On the protein level (c), densitometric
measurement (f) reveals also a reduction in ROCK1 protein expression to
34.0 % (seq1), 74.4 % (seq3) for D54MG, and 79.7 % (seq1) and 47.0 %
(seq3) for 86HG39. ROCK2 expression in ROCK1 knockdown clones is
also affected as D54MG seq1 reveals a 79.5% expression of ROCK2 and
86HG39 seq3 of 39.8 %. Quantification of ROCK2 knockdown with two
different shRNA sequences (seq2 and seq4) and a control (set as 100 %)
at the mRNA level (b) reveals a reduced ROCK2 expression levels to
13.4 and 5.7 % for D54MG cells and 2.7 and 3.9 % for 86HG39 cells. On
the protein level (d , g ), we found reductions of ROCK2 protein
expression to 51.7 % (seq2) and 87.8 % (seq4) for D54MG and 53.9 %
(seq2) and 33.2 % (seq4) for 86HG39. ROCK1 protein expression was
not influenced by ROCK2 knockdown. Using the inhibitor Y27632 (e),
we could verify a knockdown of both ROCK1 and ROCK2 on the protein
level in both cell lines. Immunofluorescence staining of the 86HG39 and
D54MG cell lines with ROCK1 (h) and ROCK2 (i) knockdown shows
changes in cell morphology (indicated by white arrows ) in ROCK
knockdown cells relative to control cells with normal ROCK expression
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Y27632-treated control cells (i.e., without ROCK1 knock-
down), only 39.7±1.93 % of the cells were located on
BM while 60.3±1.93 % were on myelin. This change in sub-
strate preference was even more marked in the Y27632-treated
ROCK1 knockdown cells (seq1, 36.9±2.44% on BMvs. 63.1±
2.44 % on myelin; seq3, 35.5±2.02 % on BM vs. 64.5±2.02 %
onmyelin). This indicates that while ROCK1 alone can influence
the substrate specificity, the inhibition of both ROCKs not only
changes the specificity from approximately 70/30 to 50/50 but
also completely switches the cells’ preference toward myelin.
The 86HG39 cell line yielded comparable results (Fig. 5), with a
switch of the cells’ preference from BM to myelin with the
ROCK inhibitor and ROCK1 knockdown clones compared to
untreated 86HG39 control cells.
Fig. 4 Different migration assays using the D54MG and 86HG39 glioblas-
toma cell lines with ROCK inhibitor Y27632 and ROCK1/ROCK2 knock-
down. In a coated radial monolayer migration assay, the cells displayed a
reduction in cell migration when treated with the ROCK inhibitor Y27632
(a). Cells with a stable ROCK1 knockdown exhibited enhanced cell
migration using a wound-healing assay on an uncoated surface (b), but a
significant decrease in cell migration using a radial monolayer assay on a
laminin-coated surface (d). Glioma cell lines with a stable ROCK2 knock-
down exhibited an increase in migration on both the uncoated surface (c) and
the laminin-coated surface (e) (*p<0.05; **p<0.001, n=3, mean±SEM)
Fig. 5 Quantification of D54MG and 86HG39 cells with altered ROCK1
expression and effects of the addition of the ROCK inhibitor Y27632 on
preferences toward different substrates in the stripe assay. a
Immunohistological staining revealing the structure of two alternate
stripes, biomatrix (BM , red) vs. myelin (M , green), without cells. b
D54MG cells (nuclei stained in blue) displaying a 70:30 distribution on
BM (red) vs. M (no staining). c ROCK1 knockdown D54MG cells
switched the substrate preference to a 55:45 distribution. d Additional
administration of Y27632 led to a 35:65 distribution. Changes in cell
distribution for ROCK1 knockdown D54MG cells plus ROCK inhibitor
growing onBMvs.myelin (e), BMvs. unmyelinated retina (g), andmyelin
vs. unmyelinated retina (i). The same setting was used with ROCK1
knockdown 86HG39 glioma cells with ROCK inhibitor growing on BM
vs. myelin (f ), BM vs. unmyelinated retina (h ), and myelin vs.
unmyelinated retina (j) (*p<0.05; **p<0.001, n=3, mean±SEM)
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Comparison of BM and the retina revealed a preference of
untreated D54MG glioma cells for BM (70.6±1.78 % for BM
vs. 29.5±1.78 % for retina). Changing the expression of
ROCK1 resulted in an alteration of the substrate preference
of the ROCK1 knockdown cells toward the retina. Both
ROCK1 knockdown clones exhibited a cell distribution of
47.5±2.1 % in BM vs. 52.5±2.1 % in the retina for clone
seq1 and of 47.5±1.8 % on BM vs. 52.5±1.8 % on the retina
for clone seq3. The switching of the substrate preference was
more pronounced following the addition of Y27632 to the
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ROCK1 knockdown cell clones, whereby the cell distribu-
tions were 33.5±1.9 % on BM vs. 66.5±1.9 % on the retina
for clone seq1 and 33.4±1.5 % on BM vs. 66.6±1.5 % on the
retina for clone seq3. Again, the 86HG39 glioblastoma cell
line behaved in a similar way, such that 73.3±1.6 % of the
untreated cells were found in BM and only 24.7±1.6 % of the
cells were located in the retina. Knockdown of ROCK1
resulted in a change in the preferred cell location toward the
retina: 48.7±1.3 % on BM vs. 51.3±1.3 % in the retina for
clone seq1 and 51.0±1.2 % in BM vs. 49.1±1.2 % in the retina
for clone seq3. The inhibitor Y27632 enhanced the effect of
ROCK1 knockdown alone to distributions of 35.9±1.5 % in
BM vs. 64.1±1.5 % in the retina for clone seq1 and of 34.1±
1.5 % in BM vs. 65.9±1.5 % in the retina for clone seq3.
To clarify the preference of the cells toward myelin, in a
third step, the retina was compared with purified myelin. In
this approach, ROCK1 inhibition also led to a switch of the
substrate specificity of all tested ROCK1 clones in both cell
lines used (Fig. 5i, j). An additional dose of 100 μM Y27632
led to a further increase in the change in substrate specificity
of the ROCK1 knockdown clones (Fig. 5i, j). Whether these
additive effects of the ROCK inhibitor Y27632 are attribut-
able to a combination of ROCK1 and ROCK2 inhibition or
are purely the effect of a nearly 100 % inhibition of ROCK1
warrants further investigation.
The cell lines with a stable ROCK2 knockdown exhibited
only slight changes in substrate preference compared to the
control cells. Comparison of the BM with myelin substrates
for the ROCK2 knockdown D54MG cells revealed cell con-
tributions (BM vs. myelin) of 72.3±1.74 % vs. 27.7±1.74 %
for control cells, 57.0±1.41 % vs. 43.0±1.41 % for seq2, and
76.2±2.15% vs. 23.8±2.15% for seq4. The 86HG39 cell line
displayed a similar distribution of cells on the two substrates
(BM vs. myelin): 72.3±1.86 % vs. 27.7±1.86 % for control
cells, 48.7±1.70 % vs. 51.3±1.70 % for seq2, and 61.8±
1.44 % vs. 38.2±1.44 % for seq4. In contrast to ROCK1
knockdown, only slight or no changes in cell distribution were
observed in ROCK2 knockdown cells (Fig. 6a).
Testing BM against the retina revealed a preference for
BM in control cells (BM vs. retina: 72.1±1.74 % vs. 27.9±
1.74 % and 72.7±1.86 % vs. 27.3±1.86 %) and a slight
shift but no significant change in preference for all four
ROCK2 knockdown clones, to 57.10±0.53 % vs. 42.90±
0.53 % (BM vs. retina). Furthermore, ROCK2 knockdown
enhanced the preference toward the retina, but did not
induce the same change in substrate preference as found
for ROCK1 knockdown (Fig. 6b). The cell distributions were
56.4±2.67 % vs. 43.6±2.67 % (D54MG control), 80.6±
1.33 % vs. 19.4±1.33 % (D54MG seq2), 50.1±2.15 % vs.
49.9±2.15 % (D54MG seq4), 52.8±2.62 % vs. 47.2±2.62 %
Fig. 6 Influence of ROCK2 knockdown on cell substrate preferences
using the stripe assay. a Testing Biomatrix vs. myelin using ROCK2
knockdown D54MG and 86HG39 cells revealed only slight changes in
cell preference with altered ROCK2 expression. b For biomatrix vs.
unmyelinated retina, ROCK2 knockdown led again to a slight switch of
about 10 % in cell preference. c Testing myelin vs. unmyelinated retina
revealed a substrate preference change in only one sequence of each cell
line from a 55:45 to a 75:25 distribution toward myelin (*p <0.05;
**p <0.001, n=3, mean±SEM)
Fig. 7 Signaling pathway analyses of cells with altered ROCK1 and
ROCK2 expressions. The expression levels of several different proteins
in the ROCK1 knockdown cells (a), ROCK2 knockdown cells (b), and
cells treated with Rho kinase inhibitor Y27632 (c ) are shown.
Densitometric measurement of protein expression of phosphoLIMK
(d ), phosphoCDC42/Rac (e ), cyclinD1 (f ), AKT1 (g ), and
phosphoAKT (h ) displayed different influences of ROCK1 and
ROCK2 on protein expression. Using Y27632, we found nearly the
same protein regulation as in cells with only ROCK1 knockdown
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(86HG39 control), 53.2±1.87 % vs. 47.8±1.87 % (86HG39
seq2), and 65.4±1.60 % vs. 34.6±1.60 % (86HG39 seq4),
indicating no changes in substrate specificity in ROCK2
knockdown cells.
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Signaling of ROCK Knockdown
The pathways involved in the effects of ROCK knockdown in
glioblastoma cells were analyzed using Western blot analysis to
determine the protein expression levels of phosphoLimK,
phosphoRac1/cdc42, cyclin D1, Akt1, phosphoAkt, β1-
integrin, β-catenin, phosphoERK1/2, and RhoA in cells with a
stable ROCK1 and ROCK2 knockdown (Fig. 7a, b) as well as in
Fig. 8 Second part of signaling pathway analyses of cells with altered
ROCK1 and ROCK2 expressions. Here, we analyzed the protein expres-
sion of RhoA (d), β1-integrin (e), β-catenin (f), pERK1 (g), and pERK2
(h) using densitometric measurement in cells with ROCK1 knockdown
(a), ROCk2 knockdown (b), and cells treated with Rho kinase inhibitor
Y27632 (c)
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glioma cells treated with 100 μM of Rho kinase inhibitor
(Fig. 7c). Although a reduced level of ROCK2 was observed
in cells with a stable ROCK1 knockdown, indicating a relation-
ship between the expression levels of ROCK1 and ROCK2,
downregulation of ROCK2 did not affect the expression level
of ROCK1 (Fig. 2c, d). ROCK1 and ROCK2 affected the
regulation of phosphoRac1/cdc42 (ser71) differently, with a
reduction of ROCK1 leading to a decrease in the phosphoryla-
tion status of Rac1/cdc42 in three out of four clones, whereas a
reduction of ROCK2 had the opposite effect in all four clones.
Only 86HG39 seq1 cells yielded an enhancement in the phos-
phorylation of Rac1/cdc42 under ROCK1 knockdown. ROCK1
knockdown reduced cyclin D1 expression, except line 86HG39
seq1, and ROCK2 knockdown increased cyclin D1, except
86HG39 seq4. Using pERK1/2, we could show that ROCK1
knockdown leads to an inhibition of ERK activity and that
ROCK2 knockdown leads to the opposite effect and enhances
the phosphorylation of ERK1/2 in all tested clones (Fig. 8g, h).
ROCK1 knockdown slightly affects Akt1 expression,
while phosphorylated Akt1 normalized to Akt1 expression
displayed a reduction in ROCK1 knockdown clones
D54MG seq1 and seq3, but an increase in all four ROCK2
knockdown clones (Fig. 7i). Using the inhibitor Y27632, both
cell lines—D54MG and 86HG39—show a reduction in
phosphoAkt1 expression compared to the control cells.
ROCK1 and ROCK2 knockdown decreased the expression
of RhoA in the D54MG cell line; the 86HG39 cell line
showed inconsistent results. Both ROCK1 and ROCK2
displayed an influence on β1-integrin and β-catenin expres-
sions. The reduction of ROCK1 or ROCK2 expression leads
in three out of four tested clones to a reduction in β1-integrin
and β-catenin expressions as well. By inhibiting both kinases,
β1-integrin protein expression was reduced in D54MG and
86HG39 cell lines, but β-catenin expression shows a reduc-
tion of expression only in the cell line 86HG39, not for the cell
line D54MG (Fig. 7 d–f).
Using the glioma cell lines D54MG and 86HG39 treated with
100μMRho kinase inhibitor, nearly all tested proteins displayed
the same regulation as in the cells with ROCK1 knockdown.
Only for β-catenin did we find no significant changes in expres-
sion in the cell line D54MG treated with Y27632.
Discussion
This study has shown that inhibition of ROCK1 and ROCK2
has a significant and differential influence on cell migration
and proliferation. ShRNAwas used to downregulate ROCK1
and ROCK2 expressions in the D54MG and 86HG39 glio-
blastoma cell lines, and the effects on cell migration, prolifer-
ation, substrate-dependent migration, and signaling pathways
were compared. After verifying the knockdown at both the
mRNA and protein levels in all the used cell lines and clones
for both ROCK1 and ROCK2 knockdown, we examined
changes in cell shape and morphology. There was no pheno-
typic difference between ROCK1 and ROCK2 knockdown
cells with respect to morphology, indicating that the two
ROCKs exert comparable influences on the cell cytoskeleton.
Inhibition of ROCK1 resulted in a decreased proliferation,
whereas inhibition of ROCK2 had the opposite effect, signif-
icantly enhancing proliferation relative to the control cells and
regulating cyclin D1, whose role is also apparent in fibroblasts
[22], corneal epithelial cells, and hepatic stellate cells [23, 24],
to mediate the canonical Wnt/TCF pathways involving β-
catenin [25, 26]. In contrast to the opposing effects of the
ROCKs described here, only ROCK2 was involved in cell
proliferation changes in SH-SY5Y cells [27], indicating
different pathways among cell lines. The influence of both
Rho kinases on proliferation was additionally shown by
analyzing the expression of EKR1/2 phosphorylation.
ROCK1 knockdown reduces the level of phosphorylation,
whereas ROCK2 knockdown leads to an increase in ERK
activity.
Expanding on the effects on cell proliferation, we analyzed
the effects of ROCK1 and ROCK2 knockdown on cell mi-
gration using different migration substrates that are natural
partners of migrating cells within the brain. Strikingly, a
significant increase in cell migration for both ROCK1 and
ROCK2 knockdown cells using the wound-healing scratch
assay was shown, contrasting previous reports using different
inhibitors [28, 29]. ROCK1 knockdown cells plus the ROCK
inhibitor Y27632 migrated more slowly than the control cells
on laminin, whereas cells with a ROCK2 knockdown migrat-
ed faster than the control and ROCK1 knockdown cells. These
findings indicate that the migration effect of ROCK1 is
substrate-dependent, while that of ROCK2 is not.
This substrate dependency of glioma cells with altered
ROCK expression was further scrutinized by conducting ex-
periments with a stripe assay [21, 30, 31]. Untreated cells
exhibited a significant substrate preference for BM [17].
ROCK1 knockdown cells changed their preference and mi-
grated preferably toward unmyelinated retina and myelin
compared to BM. This ROCK knockdown-induced prefer-
ence toward myelin is not surprising since a hallmark of
glioma migration is the long-distance movement of these cells
along myelin-rich white matter tracts [3, 5, 32]. This behavior
was confirmed in the stripe assay showing that reduced
ROCK1 also changed the substrate preference of the cells.
Addition of the ROCK inhibitor Y27632 to ROCK knock-
down cells led to an almost complete switch in substrate
preference toward the myelinated substrate, indicating an
additive pharmacological effect, while the results of the same
setup with ROCK2 knockdown cells were not as distinct.
Indeed, comparison of BM and myelin as migration substrates
revealed that only one shRNA sequence out of several tested
in both cell lines changed the specificity from a 70/30 to a 55/
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45 distribution of cells. This finding indicates that the sub-
strate dependence of glioma cells is mediated by ROCK1, not
by ROCK2. Alternatively, a balanced and simultaneous regu-
lation of both kinases may be in play, given that ROCK1
knockdown also influences ROCK2 expression, and not con-
versely, and cells with ROCK1 knockdown displayed the
same regulatory effects onmigration and proliferation as those
treated with Y27632. Furthermore, analyzing downstream
pathways in cells treated with Rho kinase inhibitor Y27632,
we found in nearly all examined proteins the same regulation
as in cells with ROCK1 knockdown. Although the two ROCK
isoforms display an 80 % homology, ROCK1 is likely oper-
ating upstream of ROCK2 and is the key regulator of the
activity of both kinases.
A driving force of cell movement is essential for cell
migration, and this force is provided mostly by reorganization
of the cytoskeleton, with directed protrusions at the front of
the cells and cell detachment at the rear [9, 33, 34]. This
reorganization of the cytoskeleton is mediated by members
of the Rho family of GTPases, such as Rho, Rac, and Cdc42
[35]. Comparison of the expression of Cdc42/Rac in cells with
ROCK1 and ROCK2 knockdown revealed that a reduction of
ROCK1 also reduces the phosphorylation of Cdc42/Rac, but a
reduction of ROCK2 increases the phosphorylation of Cdc42/
Rac. Rac and Cdc42 regulate the polymerization of actin
through the activation of Scar/WAVE and WASP/N-WASP
complexes [36, 37], while phosphorylation of cdc42/rac1on
Ser71 is assumed to attenuate the actin-driven motility. A
decreased phosphorylation was observed in ROCK1 knock-
down clones in the present study, together with reduced mi-
gration and proliferation, indicating the drastic remodeling of
the cell morphology rather than changes in migration capabil-
ity. As anticipated, inhibition of the expression of ROCK2 led
to the opposite effect on Cdc42/Rac, with increased phosphor-
ylation of Cdc42/Rac associated to increased migration.
Interestingly, both ROCK1 and ROCK2 knockdown result-
ed in a decreased RhoA protein. This suggests the presence of a
feedback loop of ROCK expression on RhoA since ROCK1
and ROCK2 are downstream effectors of RhoA in glioma cells.
This pathway may be regulated by phosphorylation, and there-
by inactivation of p190 Rho GTPase-activating protein (p190A
RhoGAP), since it was shown that in smooth muscle cells,
ROCKs are involved in the induction of RhoA activity through
the phosphorylation of p190A RhoGAP [38].
Dynamic regulation of the actin cytoskeleton is the main
factor in cell motility and cell division, involving the phos-
phorylation of LIMK. The activation of ROCK by Rho leads
to the LIMK-mediated inactivation of cofilin and results in the
accumulation of actin and the formation of lamellipodia by
inhibiting the actin depolymerization function of cofilin [39].
Interestingly, inhibition of ROCK1 and ROCK2 in the present
study led to enhanced phosphorylation of LIMK in both cell
lines and in all of the tested shRNA sequences. Rac also
activates LIMK, thereby affecting the phosphorylation of
cofilin, but reduces actomyosin-based cell contractility [40,
41]. The enhancement of LIMK phosphorylation in the
ROCK1 knockdown cells might therefore occur by enhanced
activation of Rac. Since ROCK2 knockdown leads to the
inactivation of Cdc42/Rac, the enhanced LIMK phosphoryla-
tion might be based on a different pathway and may be the
result of reduced ROCK1 expression, which is unaffected in
ROCK2 knockdown cells.
The upstream factors involved in the effects of ROCK knock-
down were identified by further analyzing the expression of β1-
integrin. Integrin clustering and focal complex formation require
the activity of Rho family members [42] such as p190A
RhoGAP, which disrupts integrin clustering [43]. Interestingly,
the influence of integrins on various cell activities such as actin
remodeling and proliferation is not limited to one direction. The
integrin ligand-binding activity can also be regulated from sig-
nals inside the cells [44, 45]. Cell signaling from inside-out to
integrins is thought to be mediated by phosphatidylinositol 3-
kinase [46] regulated by ROCK [47–49]. This regulation is
confirmed in the present studywhich shows that ROCK1 knock-
down leads to a decrease in β1-integrin expression and a slight
increase in Akt expression, without significantly affecting Akt
phosphorylation. We observed similar changes in β1-integrin
expression in ROCK knockdown cells, but also a significant
progression of Akt phosphorylation mediated by ROCK2, but
not by ROCK1.
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